Join the Dexamethasone group to help and get support from people like you.
Dexamethasone News
Related terms: Dexamethasone Topical, Dexamethasone Ophthalmic, Dexamethasone Nasal, Dexamethasone Otic
High-Dose Glucocorticoids No Better Than Low-Dose for Sudden Hearing Loss
WEDNESDAY, Jan. 10, 2024 – For patients with idiopathic sudden sensorineural hearing loss (ISSNHL), systemic high-dose glucocorticoid therapy is no better than a lower-dose regimen, according to a...
Dexamethasone No Benefit in HIV-Positive With Tuberculous Meningitis
THURSDAY, Oct. 12, 2023 – For HIV-positive adults with tuberculous meningitis, adjunctive dexamethasone does not confer a benefit with respect to survival, according to a study published in the Oct....
Could Cold Air Help Settle a Case of Croup? New Study Says Yes
TUESDAY, Aug. 1, 2023 – Pediatricians have suspected it for years, and now a new study may be proving them right: Cold air really can help ease children's croup symptoms. Croup is a common childhood...
Exposure to Outdoor Cold Air Beneficial for Children With Croup
TUESDAY, Aug. 1, 2023 – A 30-minute exposure to outdoor cold air is beneficial for reducing clinical symptoms in children with croup as an adjunct to oral dexamethasone, according to a study...
Dexamethasone Best for Persistent, Recurrent Uveitic Macular Edema
THURSDAY, June 22, 2023 – For patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular edema (ME), dexamethasone is significantly better for treatment than...
Dexamethasone Compared to Burr-Hole Drainage for Chronic Subdural Hematoma
THURSDAY, June 15, 2023 – For patients with chronic subdural hematoma, a 19-day tapering course of dexamethasone therapy is not noninferior to surgery with respect to functional outcomes at three...
FDA Medwatch Alert: FDA Warns Consumers Not to Purchase or Use Artri and Ortiga Products, Which May Contain Hidden Drug Ingredients
April 20, 2021 --FDA is warning consumers not to purchase or use products marketed with variations of the names “Artri” or “Ortiga” due to potentially dangerous hidden active drug ingredients not list...
FDA Medwatch Alert: Edge Pharma, LLC Issues Voluntary Nationwide Recall of All Drug Products Due to Lack of Sterility Assurance
December 4, 2021 – Colchester, VT, Edge Pharma, LLC is voluntarily recalling all lots of all drugs compounded at Edge Pharma, LLC to the consumer level. All products are being recalled due to process ...
Ocular Therapeutix Announces FDA Approval of sNDA for Dextenza (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 11, 2021-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
FDA Approves Darzalex (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible
HORSHAM, Pa., June 27, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Darzalex (daratumumab) in combination w...
Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 21, 2019-- Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative t...
FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery
BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2018-- Ocular Therapeutix™, Inc. a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for d...
FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Empliciti (elotuzumab) injection for intravenous...
Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery
Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care th...
FDA Approves Darzalex (daratumumab) in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, o...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Systemic Lupus Erythematosus, Lymphoma, Multiple Myeloma, Multiple Sclerosis, Nausea / Vomiting, Nausea / Vomiting - Chemotherapy Induced, Leukemia, Psoriasis, Psoriatic Arthritis, view more... Rheumatoid Arthritis, Seborrheic Dermatitis, Shock, Transverse Myelitis, Ulcerative Colitis, Plaque Psoriasis, Juvenile Rheumatoid Arthritis, Hay Fever, Allergic Rhinitis, Allergies, Ankylosing Spondylitis, Aphthous Ulcer, Asthma, Asthma - Acute, Contact Dermatitis, Atopic Dermatitis, Bursitis, Eczema, Inflammatory Bowel Disease, Inflammatory Conditions